Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. HOOD
5. SPY
6. CDNS
7. ANT
8. META
9. STX
10. INTC

Go back to Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c

Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update

July 27, 2017 4:06 PM EDT

NOVATO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2017.

We look forward to submitting our biologics license application (BLA) for burosumab and working with the FDA to bring this potential treatment to adult and pediatric patients, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We believe the first bone biopsy data from our ongoing Phase 3... More